What are the specific genetic mutations related to Sorafenib/Nexavar

Sorafenib/Nexavar (Sorafenib) is a classic multi-target kinase inhibitor, and its mechanism of action is highly dependent on the inhibition of tumor signaling pathways and angiogenesis-related molecules. The occurrence and progression of tumors are often closely related to multiple gene mutations and signaling abnormalities, and sorafenib exerts its anti-tumor effect by inhibiting these targets.

At the molecular level, sorafenib mainly affects cell growth and differentiation by inhibiting theRas/MAPK signaling pathway. It targets multiple isoforms of Raf serine/threonine kinase, including Raf-1 (C-Raf), wild-type B-Raf, and mutant B-Raf. Especially in some tumors, B-Raf mutations lead to abnormal activation of the downstream ERK pathway, thereby promoting unlimited cell proliferation. By interfering with these kinases, sorafenib can effectively block the transmission of malignant signals and inhibit tumor cell proliferation.

In addition, sorafenib also has a broad-spectrum inhibitory effect on receptor tyrosine kinases (RTKs), covering a variety of gene mutations related to tumor angiogenesis and cell survival. Its main targets include KIT, FLT-3, RET, RET/PTC, as well as multiple vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor-β (PDGFR-β). Among them, FLT-3 mutations play an important role in acute myeloid leukemia, and abnormal activation of VEGFR and PDGFR signaling pathways is closely related to tumor angiogenesis.

Therefore, sorafenib is thought to have a dual mechanism of action. On the one hand, it directly inhibits the growth and proliferation of tumor cells by blocking the RAF/MEK/ERK signaling pathway; on the other hand, it limits angiogenesis by inhibiting receptors such as VEGFR and PDGFR, thus cutting off the nutrient and oxygen supply to tumors. This dual mechanism provides a solid scientific basis for the application of sorafenib in the treatment of various tumors.

To sum up, the main related gene mutations of sorafenib include B-Raf, C-Raf, FLT-3, RET and multiple angiogenesis-related genes. By precisely inhibiting these target pathways, it can attack cancer cells from multiple angles.

Reference materials:https://www.nexavar.com/